CD163 and neoplasm: Furthermore, similar to the observed shift in profile from an M2-like to an M1-like macrophage induced by 19L04c observed in multiple in vitro assays, 19L04c treatment led to a significant decrease in an M2-like phenotype of the tumor-infiltrating CD11b+CD14+ macrophage population as indicated by a decrease in expression levels of CD163, a marker of M2-like macrophages (Figure 3E), and in a decrease in suppressive granulocytic macrophages identified by CD33+CD11blowMHCIIlowSSChigh (Figure 3F).